
MTCR
US listing · $25.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 16, 2023 | Time not confirmed | -0.13 | 0.00 | +100.0% |
| Nov 14, 2022 | After the close | -0.10 | -0.13 | -30.0% |
| Aug 9, 2022 | After the close | -0.25 | -0.15 | +40.0% |
| May 12, 2022 | After the close | -0.39 | -0.31 | +20.5% |
| Mar 30, 2022 | After the close | -0.63 | -0.32 | +49.2% |
| Nov 11, 2021 | Before the open | -0.61 | -0.69 | -13.1% |
| Aug 12, 2021 | Before the open | -0.60 | -0.59 | +1.7% |
| May 13, 2021 | After the close | -0.51 | -0.57 | -11.8% |
| Mar 18, 2021 | Before the open | -0.38 | -1.15 | -202.6% |
| Nov 12, 2020 | Before the open | -0.41 | -1.41 | -243.9% |
| Sep 16, 2020 | After the close | 0.00 | -0.50 | — |
| Aug 27, 2018 | Time not confirmed | — | -0.16 | — |
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.